Blood Screening Term definition

Blood Screening Term means the period commencing on the Effective Date and expiring on June 30, 2025, subject to earlier termination pursuant to and in accordance with the provisions of this Agreement.
View Source
Blood Screening Term means the period commencing on the Effective Date and expiring on the later of (a) the date [***] the First Commercial Sale of the first Blood Screening Assay in the Territory for use in the Blood Screening Field (other than any sale as may be made pursuant to Section 3.1.4(b) or Section 3.6), and (b) the date [***] the First Commercial Sale of the last Blood Screening Assay launched prior to the date specified in clause (a) above in the Territory for use in the Blood Screening Field.
View Source
Blood Screening Term means the period commencing on the Effective Date and expiring on the later of (a) the date [CONFIDENTIAL TREATMENT REQUESTED] the First Commercial Sale of the first Blood Screening Assay in the Territory for use in the Blood Screening Field (other than any sale as may be made pursuant to Section 3.1.4(b) or Section 3.6), and (b) the date [CONFIDENTIAL TREATMENT REQUESTED] the First Commercial Sale of the last Blood Screening Assay launched prior to the date specified in clause (a) above in the Territory for use in the Blood Screening Field.
View Source

Examples of Blood Screening Term in a sentence

  • From time to time during the Blood Screening Term, the Supervisory Board shall consider potential modifications to the initial Development Program for the Blood Screening Instruments and to the Blood Screening Instruments.

  • Thereafter, subject to Section 3.1.4(d) below, during the Blood Screening Term, Chiron shall have the exclusive right, at its sole cost, to promote, market and sell the Japanese HIV Qualitative Blood Screening Assay in Japan for use in the Blood Screening Field.

  • Thereafter, subject to Section 3.3.4(d) below, during the Blood Screening Term, Chiron shall have the exclusive right, at its sole cost, to promote, market and sell the Blood Screening Instruments in Japan for use in the Blood Screening Field.

  • Termination of this West Nile Virus Addendum prior to the expiration of the Blood Screening Term shall be governed by the terms of this Section and termination of the Agreement shall be governed by Section 11.2 of the Agreement.

  • Unless terminated earlier pursuant to Section 11.2 below, this Agreement shall expire (i) as to the Blood Screening Assays and the Blood Screening Instruments, on the expiration of the Blood Screening Term and (ii) as to the Clinical Diagnostic Assays and Clinical Diagnostic Instruments, on the expiration of the Clinical Diagnostic Term.

  • Unless terminated earlier pursuant to Section 10.2 below, this Agreement shall expire on the expiration of the Blood Screening Term.

  • This eSAS 2 Addendum shall become effective on the Addendum Effective Date and shall continue in effect through the Blood Screening Term, as it may be amended or extended from time to time, unless sooner terminated in accordance with the provisions hereof.

  • If Gen-Probe develops any new instrument for use with TMA Assays in the Blood Screening Field, it shall offer to grant to Chiron, during the Blood Screening Term and on reasonable terms to be negotiated, rights to such instrument comparable to the rights granted under this Agreement as to the Blood Screening Instruments existing on the Effective Date, to the extent that Gen-Probe reasonably ***Certain information on this page has been omitted and filed separately with the Commission.

  • This West Nile Virus Addendum shall become effective on the Addendum Effective Date and shall continue in effect through the Blood Screening Term, unless sooner terminated in accordance with the provisions hereof.

  • From time to time during the Blood Screening Term, the Supervisory Board shall consider potential modifications to the Products.